Safety of MET Tyrosine Kinase Inhibitors in Patients with MET Exon 14 Skipping Non-small Cell Lung Cancer: A Clinical Review
出版年份 2022 全文链接
标题
Safety of MET Tyrosine Kinase Inhibitors in Patients with MET Exon 14 Skipping Non-small Cell Lung Cancer: A Clinical Review
作者
关键词
Adverse events, NSCLC, Safety management, TKIs, Peripheral edema
出版物
Clinical Lung Cancer
Volume -, Issue -, Pages -
出版商
Elsevier BV
发表日期
2022-02-05
DOI
10.1016/j.cllc.2022.01.003
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
- (2021) Hyuna Sung et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Capmatinib in Japanese patients with MET exon 14 skipping–mutated or MET ‐amplified advanced NSCLC: GEOMETRY mono‐1 study
- (2021) Takashi Seto et al. CANCER SCIENCE
- Targeted Therapy in Advanced and Metastatic Non-Small Cell Lung Cancer. An Update on Treatment of the Most Important Actionable Oncogenic Driver Alterations
- (2021) David König et al. Cancers
- Once-daily savolitinib in Chinese patients with pulmonary sarcomatoid carcinomas and other non-small-cell lung cancers harbouring MET exon 14 skipping alterations: a multicentre, single-arm, open-label, phase 2 study
- (2021) Shun Lu et al. Lancet Respiratory Medicine
- P47.17 Capmatinib vs Docetaxel in Pretreated Patients With MET Exon 14 Skipping–mutated Stage IIIB/IIIC or IV NSCLC (GeoMETry-III)
- (2021) P. Souquet et al. Journal of Thoracic Oncology
- Antitumor activity of crizotinib in lung cancers harboring a MET exon 14 alteration
- (2020) Alexander Drilon et al. NATURE MEDICINE
- Tepotinib: First Approval
- (2020) Anthony Markham DRUGS
- Variation in Toxicity Reporting Methods for Early Phase Lung Cancer Treatment Trials at Oncology Conferences
- (2020) Emily A. Simons et al. Journal of Thoracic Oncology
- Tepotinib in Non–Small-Cell Lung Cancer with MET Exon 14 Skipping Mutations
- (2020) Paul K. Paik et al. NEW ENGLAND JOURNAL OF MEDICINE
- MET Oncogene in Non-Small Cell Lung Cancer: Mechanism of MET Dysregulation and Agents Targeting the HGF/c-Met Axis
- (2020) Hongge Liang et al. OncoTargets and Therapy
- A case of ROS1 ‐rearranged lung adenocarcinoma exhibiting pleural effusion caused by crizotinib
- (2020) Hiroaki Tachi et al. Thoracic Cancer
- Molecular correlates of response to capmatinib in advanced non-small-cell lung cancer: clinical and biomarker results from a phase I trial
- (2020) M. Schuler et al. ANNALS OF ONCOLOGY
- Interstitial Lung Disease as an Adverse Drug Reaction in Japan: Exploration of Regulatory Actions as a Basis for High Reporting
- (2020) Eiko Iwasa et al. DRUG SAFETY
- Capmatinib: First Approval
- (2020) Sohita Dhillon DRUGS
- 1285P Capmatinib in patients with METex14-mutated advanced non-small cell lung cancer who received prior immunotherapy: The phase II GEOMETRY mono-1 study
- (2020) J.F. Vansteenkiste et al. ANNALS OF ONCOLOGY
- 584P Tepotinib exposure-response analyses of safety and efficacy in patients with solid tumours
- (2020) P.K. Paik et al. ANNALS OF ONCOLOGY
- Capmatinib in MET Exon 14–Mutated or MET-Amplified Non–Small-Cell Lung Cancer
- (2020) Jürgen Wolf et al. NEW ENGLAND JOURNAL OF MEDICINE
- New Verse for a Familiar Song: Small Molecule Inhibitors for MET exon 14 Skipping Non‐Small Cell Lung Cancer
- (2020) Xiuning Le et al. ONCOLOGIST
- Current Status of Novel Biomarkers for the Diagnosis of Acute Kidney Injury: A Historical Perspective
- (2019) Benjamin R. Griffin et al. JOURNAL OF INTENSIVE CARE MEDICINE
- Renal Effects of Crizotinib in Patients With ALK-Positive Advanced Non-Small Cell Lung Cancer
- (2019) David Ross Camidge et al. Journal of Thoracic Oncology
- Crizotinib in MET deregulated or ROS1 rearranged pretreated non-small-cell lung cancer (METROS): a phase II, prospective, multicentre, two-arms trial
- (2019) Lorenza Landi et al. CLINICAL CANCER RESEARCH
- 62OTepotinib in NSCLC patients harboring METex14 skipping: Cohort A of phase II VISION study
- (2019) K Park et al. ANNALS OF ONCOLOGY
- Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC
- (2019) Suresh S. Ramalingam et al. NEW ENGLAND JOURNAL OF MEDICINE
- Effect of tyrosine kinase inhibitors on renal handling of creatinine by MATE1
- (2018) Saki Omote et al. Scientific Reports
- Crizotinib versus Chemotherapy in Asian Patients with ALK-Positive Advanced Non-small Cell Lung Cancer
- (2018) Makoto Nishio et al. Cancer Research and Treatment
- Hypoalbuminemia: Pathogenesis and Clinical Significance
- (2018) Peter B. Soeters et al. JOURNAL OF PARENTERAL AND ENTERAL NUTRITION
- Immune-checkpoint inhibitors associated with interstitial lung disease in cancer patients
- (2017) Myriam Delaunay et al. EUROPEAN RESPIRATORY JOURNAL
- Intracranial Activity of Cabozantinib in MET Exon 14–Positive NSCLC with Brain Metastases
- (2017) Samuel J. Klempner et al. Journal of Thoracic Oncology
- The race to target MET exon 14 skipping alterations in non-small cell lung cancer: The Why, the How, the Who, the Unknown, and the Inevitable
- (2017) Thanyanan Reungwetwattana et al. LUNG CANCER
- Thoracic radiation-induced pleural effusion and risk factors in patients with lung cancer
- (2017) Jing Zhao et al. Oncotarget
- MET Amplification and Exon 14 Splice Site Mutation Define Unique Molecular Subgroups of Non-Small Cell Lung Carcinoma with Poor Prognosis
- (2016) J. H. Tong et al. CLINICAL CANCER RESEARCH
- MET Exon 14 Mutations in Non–Small-Cell Lung Cancer Are Associated With Advanced Age and Stage-Dependent MET Genomic Amplification and c-Met Overexpression
- (2016) Mark M. Awad et al. JOURNAL OF CLINICAL ONCOLOGY
- Characterization of 298 Patients with Lung Cancer Harboring MET Exon 14 Skipping Alterations
- (2016) Alexa B. Schrock et al. Journal of Thoracic Oncology
- Large-scale screening for somatic mutations in lung cancer
- (2016) Rafael Rosell et al. LANCET
- MET exon 14 skipping defines a unique molecular class of non-small cell lung cancer
- (2016) Difan Zheng et al. Oncotarget
- Incidence of Programmed Cell Death 1 Inhibitor–Related Pneumonitis in Patients With Advanced Cancer
- (2016) Mizuki Nishino et al. JAMA Oncology
- Cystatin C as a biomarker for estimating glomerular filtration rate
- (2015) Thomas W. Ferguson et al. CURRENT OPINION IN NEPHROLOGY AND HYPERTENSION
- Expert Consensus on the Management of Adverse Events from EGFR Tyrosine Kinase Inhibitors in the UK
- (2015) R. Califano et al. DRUGS
- A safety assessment of crizotinib in the treatment of ALK-positive NSCLC patients
- (2015) Alana Dikopf et al. Expert Opinion On Drug Safety
- Activation of MET via Diverse Exon 14 Splicing Alterations Occurs in Multiple Tumor Types and Confers Clinical Sensitivity to MET Inhibitors
- (2015) G. M. Frampton et al. Cancer Discovery
- Validation of Cell-Cycle Arrest Biomarkers for Acute Kidney Injury Using Clinical Adjudication
- (2014) Azra Bihorac et al. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE
- Development of the National Cancer Institute's Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE)
- (2014) E. Basch et al. JNCI-Journal of the National Cancer Institute
- Crizotinib Effects on Creatinine and Non-Creatinine–Based Measures of Glomerular Filtration Rate
- (2014) D. Ross Camidge et al. Journal of Thoracic Oncology
- Comprehensive molecular profiling of lung adenocarcinoma
- (2014) Eric A. Collisson et al. NATURE
- Symptomatic reduction in free testosterone levels secondary to crizotinib use in male cancer patients
- (2013) Andrew J. Weickhardt et al. CANCER
- Drug-induced reduction in estimated glomerular filtration rate in patients with ALK-positive non-small cell lung cancer treated with the ALK inhibitor crizotinib
- (2013) Evelyn M. Brosnan et al. CANCER
- EMD 1214063 and EMD 1204831 Constitute a New Class of Potent and Highly Selective c-Met Inhibitors
- (2013) F. Bladt et al. CLINICAL CANCER RESEARCH
- Crizotinib versus Chemotherapy in Advanced ALK-Positive Lung Cancer
- (2013) Alice T. Shaw et al. NEW ENGLAND JOURNAL OF MEDICINE
- The Role of Vascular Endothelial Growth Factor in the Pathogenesis, Diagnosis and Treatment of Malignant Pleural Effusion
- (2013) Michael Bradshaw et al. Current Oncology Reports
- Rapid-onset hypogonadism secondary to crizotinib use in men with metastatic nonsmall cell lung cancer
- (2012) Andrew J. Weickhardt et al. CANCER
- Practice guidance on the management of acute and chronic gastrointestinal problems arising as a result of treatment for cancer
- (2011) H Jervoise N Andreyev et al. GUT
- Crizotinib: a novel and first-in-class multitargeted tyrosine kinase inhibitor for the treatment of anaplastic lymphoma kinase rearranged nonsmall cell lung cancer and beyond
- (2011) Sai-Hong Ignatius Ou Drug Design Development and Therapy
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started